In colorectal cancer, SREBP1 promotes resistance of 5-FU through inhibition of caspase7 expression and reduction of PARP1 cleavage fragments, potentially providing a novel target in cancer therapy (Fig. 4).70 This evidence concerns the gene SREBF1 and colorectal cancer.